3.05
+0.11(+3.74%)
Currency In USD
| Previous Close | 2.94 |
| Open | 2.97 |
| Day High | 3.05 |
| Day Low | 2.89 |
| 52-Week High | 6.33 |
| 52-Week Low | 1.2 |
| Volume | 845,086 |
| Average Volume | 997,364 |
| Market Cap | 173.65M |
| PE | 12.71 |
| EPS | 0.24 |
| Moving Average 50 Days | 2.78 |
| Moving Average 200 Days | 2.26 |
| Change | 0.11 |
If you invested $1000 in Black Diamond Therapeutics, Inc. (BDTX) since IPO date, it would be worth $81.33 as of September 09, 2025 at a share price of $3.05. Whereas If you bought $1000 worth of Black Diamond Therapeutics, Inc. (BDTX) shares 3 years ago, it would be worth $1,037.41 as of September 09, 2025 at a share price of $3.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 12:00 PM GMT
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announce
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
GlobeNewswire Inc.
Mar 19, 2025 11:00 AM GMT
The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Nov 05, 2024 1:00 PM GMT
Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 Presented real-world treatment practices and patient ou